BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35494035)

  • 1. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
    Diefenbach RJ; Lee JH; Stewart A; Menzies AM; Carlino MS; Saw RPM; Stretch JR; Long GV; Scolyer RA; Rizos H
    Front Oncol; 2022; 12():820510. PubMed ID: 35494035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
    Diefenbach RJ; Lee JH; Menzies AM; Carlino MS; Long GV; Saw RPM; Howle JR; Spillane AJ; Scolyer RA; Kefford RF; Rizos H
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32785074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive droplet digital PCR method for detection of
    McEvoy AC; Calapre L; Pereira MR; Giardina T; Robinson C; Khattak MA; Meniawy TM; Pritchard AL; Hayward NK; Amanuel B; Millward M; Ziman M; Gray ES
    Oncotarget; 2017 Oct; 8(45):78890-78900. PubMed ID: 29108273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
    Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
    Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic
    Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Frénard C; Varey E; Hofman P; Khammari A; Dréno B; Denis MG
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664549
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 7. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
    PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
    Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
    Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
    Váraljai R; Wistuba-Hamprecht K; Seremet T; Diaz JMS; Nsengimana J; Sucker A; Griewank K; Placke JM; Horn PA; von Neuhoff N; Shannan B; Chauvistré H; Vogel FCE; Horn S; Becker JC; Newton-Bishop J; Stang A; Neyns B; Weide B; Schadendorf D; Roesch A
    JCO Precis Oncol; 2020; 3():. PubMed ID: 32914028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
    Fitzgerald S; Blenkiron C; Stephens R; Mathy JA; Somers-Edgar T; Rolfe G; Martin R; Jackson C; Eccles M; Robb T; Rodger E; Lawrence B; Guilford P; Lasham A; Print CG
    Mol Diagn Ther; 2023 Jul; 27(4):537-550. PubMed ID: 37099071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
    Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
    Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
    Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
    Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.
    Calapre L; Giardina T; Robinson C; Reid AL; Al-Ogaili Z; Pereira MR; McEvoy AC; Warburton L; Hayward NK; Khattak MA; Meniawy TM; Millward M; Amanuel B; Ziman M; Gray ES
    Mol Oncol; 2019 Feb; 13(2):171-184. PubMed ID: 30312528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals.
    Suh YJ; Kwon MJ; Noh HM; Lee HK; Ra YJ; Kim NY
    Healthcare (Basel); 2021 Apr; 9(4):. PubMed ID: 33915745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.